EXHIBIT 99.1 BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update — Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — — BCX17725 for Netherton syndrome advances into the clinic — — Company generates GAAP operating pr ...

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) shows potential for significant upside, with a mean price target of $14.27 indicating a 79.5% increase from the current price of $7.95, despite some analysts predicting a decline [1] Price Targets and Analyst Consensus - The mean estimate consists of 11 short-term price targets with a standard deviation of $6.71, indicating variability in analyst predictions [1] - The lowest estimate is $7, suggesting a 12% decline, while the highest estimate is $30, indicating a potential surge of 277.4% [1] - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement direction [4] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising BCRX's earnings estimates higher, which correlates with potential stock price increases [2][5] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5.2%, with no negative revisions [5] - BCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [5] Caution on Price Targets - Price targets can mislead investors, as empirical research indicates they often do not accurately predict stock price movements [3] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [3] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [4]

BioCryst Pharmaceuticals (BCRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ...

| --- | --- | --- | |----------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Second Quarter 2024 Results Call | | | | Co rpo ra te U pd a te & F ina nc ia l R esults August 5, 2024 | | | | CONFID ENTIAL & PRO PRIETA RY | | | Forward-looking statements BioCryst's presentation contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These s ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Chris Raymond - Piper Sandler Gena Wang - Barclays Maury Raycroft - Jefferies Stacy Ku - TD Cowen Jon Wolleben - JMP Securities Ser ...

EXHIBIT 99.1 BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update —Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals ...

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the second quarter ended June 30, 2024, ...

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, ...

Company Overview - BioCryst Pharmaceuticals (BCRX) is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year change of +20.8% [2] - Revenues are anticipated to be $98.27 million, which is a 19.1% increase from the same quarter last year [2] - The Most Accurate Estimate for BioCryst is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.62% [5] Earnings Expectations - The upcoming earnings report is scheduled for August 5, and the stock price may react positively if actual results exceed expectations [1] - Conversely, if the results fall short, the stock may decline [1] - The consensus EPS estimate has been revised 2.7% lower over the last 30 days, indicating a reassessment by analysts [2] Historical Performance - In the last reported quarter, BioCryst was expected to post a loss of $0.23 per share but actually reported a loss of $0.17, resulting in a surprise of +26.09% [7] - Over the past four quarters, BioCryst has beaten consensus EPS estimates three times [7] Industry Context - In the Zacks Medical - Drugs industry, Ardelyx (ARDX) is expected to post a loss of $0.10 per share, indicating a year-over-year change of -25% [9] - Ardelyx's revenue is projected to be $55.73 million, up 149.6% from the previous year [9] - The consensus EPS estimate for Ardelyx has been revised 14% higher in the last 30 days, resulting in a positive Earnings ESP of 3.92% [9]